A Phase 3 interventional study of YJ001 spray simulant and YJ001 spray in Diabetic Peripheral Neuropathic Pain (DPNP), sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Neuralgia with a site in China — 16 open to participants now, 16 under way, 1 of them phase 3. Neuralgia · China.
Among the 40 studies in Neuralgia with a site in China, this one is the 2nd largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 14 of the 15 other live ones, and was the 39th registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →16 of the 40 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Beijing Tiantan Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 6 · Phase 4 2
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 158 across the 30 interventional studies, 300 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 40 have an industry lead sponsor. The 10 most frequent:
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuralgia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06766916Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCrisugabalin for Radiotherapy-Related Neuropathic Pain | 2026-11-30 |
| NCT06596681Beijing Tiantan HospitalA Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain | 2026-12-31 |
| NCT07148388Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAccelerated Intermittent Theta Burst Stimulation (AiTBS)on Neuropathic Pain | 2027-09-01 |
| NCT07699770Tang-Du HospitalCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Neuralgia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if YJ001 Spray works to treat diabetic patients with Diabetic Peripheral Neuropathic Pain..It will also learn about the safety of drug YJ001 Spray.This trial is divided into two parts. The first part of the trial is designed as a randomized, double-blind, double-dummy, parallel-controlled, multi-center clinical trial with positive reference product and placebo; the second part is designed as a single-arm, open-label, multi-center clinical trial.In the first part, the trial was divided into the test group, the positive control group, and the placebo group.
In the first part,The experimental group received YJ001 spray + clobazam besylate capsule placebo, the positive control group received YJ001 spray placebo + clobazam besylate capsule, and the placebo group received YJ001 spray placebo + clobazam besylate capsule placebo. In the second part, all participants were treated with the investigational product, and 30 trial participants underwent PK blood sample collection according to the protocol.
Part I of the trial : To evaluate the efficacy and safety of YJ001 spray in treating diabetic peripheral neuropathic pain.
Part 2 of the trial: Evaluate the long-term efficacy and the pharmacokinetic characteristics of YJ001 spray in treating dia betic peripheral neuropathic pain at the clinically recommended dosage.
Participants will:
Apply spray topically to both feet twice daily, with six sprays per foot at each administration.
Visit the clinic once every 1 or 2 or 4 weeks for checkups and tests Complete a study diary daily to record pain intensity, sleep interference, study-drug administration, and spray-related respiratory irritation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants in the second part of the trial must meet all the following criteria to be eligible for enrollment in the second part of this study.
Exclusion Criteria:
Experiment Part One
Abnormal skin conditions at the site of administration can affect the determination of test results, such as:
Active hepatitis B is defined as: hepatitis B surface antigen positive and HBV-DNA detection value exceeding the ; Active hepatitis C is defined as: positive hepatitis C antibodies and HCV-RNA detection values exceeding the upper limit of normal; Positive for Treponema pallidum antibody (TP Ab) and positive for syphilis non-specific antibody titers; Known as a human immunodeficiency virus infection, or HIV antibody test result positive.
The second part of the experiment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: YJ001 spray simulant · Drug: Crisugabalin Besilate Capsules simulant
Drug: YJ001 spray · Drug: Crisugabalin Besilate Capsules simulant
Drug: YJ001 spray simulant · Drug: Crisugabalin Besilate Capsules
spray:0 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.
spray:480 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.
capsule:20mg per dose, twice a day
0mg per dose, twice a day
Change from baseline in Average Daily Pain Score (ADPS)
Change from baseline in Average Daily Pain Score (ADPS). ADPS is collected from patient daily pain diary. The difference between YJ001 spray group and placebo group will be compared.
Time frame: Week 12
Number of participants with clinically significant changes in safety parameters from baseline
Safety parameters including adverse events (AEs), laboratory tests, physical examination, vital signs and electrocardiogram (ECG). Clinically significant changes from baseline will be assessed at Week 52 during the open-label extension part (part two).
Time frame: week 52
Compared with the placebo group, the Change from baseline in Average Daily Pain Score (ADPS) at weeks 1-11 and 13 after treatment in the test group
ADPS is collected from the average daily pain NRA score based on diary card records. The difference between YJ001 spray group and placebo group will be compared
Time frame: weeks 1-11 and 13
Compared with the positive control group, the change in Average Daily Pain Score(ADPS) from baseline to the 1-13 weeks after treatment in the test group;
ADPS is collected from the average daily pain NRA score based on diary card records.
Time frame: weeks 1-13
The response rates of ADPS (the proportion of trial participants with weekly ADPS decrease of ≥30% and ≥50% relative to baseline) in the three groups at the 12 and 13 week after treatment
Time frame: weeks 12 and 13
The proportion of trial participants with ADPS scores less than 1 in the three groups at the 12 and 13 weeks after treatment
Time frame: 12 and 13 weeks
Change from baseline in Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS) score
Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS). The scale ranges from 0 to 10. Higher scores indicate worse pain. Change from baseline in SF-MPQ-VAS scores will be compared among the three groups at Week 12 and Week 13.
Time frame: 12th and 13th weeks
Change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) total score
Short-Form McGill Pain Questionnaire (SF-MPQ). Total score ranges from 0 to 45. Higher scores indicate worse pain. Change from baseline in SF-MPQ total scores will be compared among the three groups at Week 12 and Week 13.
Time frame: 12th and 13th weeks
At the 13th week after treatment, the overall impression of pain change (PGIC) among the three groups of trial participants
Patient Global Impression of Change (PGIC). The scale ranges from 1 to 7. Lower scores indicate better improvement in pain. PGIC scores will be compared among the three groups at Week 13.
Time frame: 13th week
Changes in weekly average sleep disturbance scores from baseline at weeks 12 and 13 after treatment in the three groups
Weekly average sleep disturbance score. The scale ranges from 0 to 10. Higher scores indicate worse sleep disturbance. Change from baseline in weekly average sleep disturbance scores will be compared among the three groups at Week 12 and Week 13.
Time frame: weeks 12 and 13
Changes in Hospital Anxiety and Depression Scale (HADS) scores from baseline at the 12th and 13th weeks after treatment in the three groups
Hospital Anxiety and Depression Scale (HADS). Total score ranges from 0 to 42. Higher scores indicate greater anxiety and depression symptoms. Change from baseline in HADS scores will be compared among the three groups at Week 12 and Week 13.
Time frame: 12th and 13th weeks
Changes in Short Form-36 (SF-36) quality of life scale scores from baseline at 13 week after treatment in the three groups
Short Form-36 (SF-36) quality of life scale. Each domain score ranges from 0 to 100. Higher scores indicate better quality of life. Change from baseline in SF-36 scores will be compared among the three groups at Week 13.
Time frame: 13 week
At the 13th week after treatment, the percentage of participants using emergency medication and the total amount of emergency medication in the three groups
Time frame: 13th week
The incidence of adverse reactions leading to drug withdrawal or reduction in drug dosage in each group
Time frame: weekly
Changes in SF-MPQ score and SF-MPQ-VAS score from baseline to the 52nd week after treatment
Short-Form McGill Pain Questionnaire (SF-MPQ). Total score ranges from 0 to 45. Higher scores indicate worse pain. Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS). The scale ranges from 0 to 10. Higher scores indicate worse pain.
Time frame: 52 week
During the drug withdrawal follow-up period, changes in weekly SF-MPQ scores compared to the baseline period
Time frame: weekly
Steady-state plasma concentration at 2 hours (C2h,ss) of YJ001
Steady-state plasma concentration at 2 hours (C2h,ss) of YJ001 spray in patients with diabetic peripheral neuropathic pain. C2h,ss will be measured at Weeks 21, 25 and 52.
Time frame: weeks 21,25,52
During the drug withdrawal follow-up period, changes in weekly SF-MPQ-VAS compared to the baseline period
Time frame: weekly
Steady-state plasma concentration at 6 hours (C2h,ss) of YJ001
Steady-state plasma concentration at 6 hours (C6h,ss) of YJ001 spray in patients with diabetic peripheral neuropathic pain. C6h,ss will be measured at Weeks 21, 25 and 52.
Time frame: Weeks 21, 25 and 52
Steady-state minimum plasma concentration (Cmin,ss) of YJ001
Steady-state minimum plasma concentration (Cmin,ss) of YJ001 spray in patients with diabetic peripheral neuropathic pain. Cmin,ss will be measured at Weeks 21, 25 and 52.
Time frame: Weeks 21, 25 and 52
Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.
Of 33 phase 3 interventional studies under Neuralgia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: YJ001
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.